Lai, E. C.-C.
Lin, T.-C.
Lange, J. L.
Chen, L.
Wong, I. C. K.
Sing, C.-W.
Cheung, C.-L.
Shao, S.-C.
Yang, Y.-H. Kao http://orcid.org/0000-0003-4623-5561
Article History
Received: 10 September 2021
Accepted: 27 December 2021
First Online: 15 January 2022
Declarations
:
: Study protocol was approved by the National Cheng Kung University Institutional Review Board (HREC#107–008) in Taiwan and the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster (UW 19–154) in Hong Kong.
: For this type of study, formal consent is not required.
: Not applicable.
: ECCL has received honoraria from AbbVie, grant funding from Amgen, AbbVie and Takeda, and financial support from Taiwan’s Ministry of Science and Technology; TCL, JLL, and LC are employees and stockholders of Amgen; ICKW has received grant support from Amgen; YHKY has received grant support from Amgen; CWS, CLC, and SCS have no conflicts to disclose.